Brazikumab

N/A

Report date: 2023/11/22 20:04:33

Base Information

Drug NameBrazikumab
Drug Alias Name布雷库单抗BrazikumabumAMG-139MEDI-2070Anti-IL-23-MAb (Amgen)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-23 inhibitors
TargetsInterleukin-23
Therapy Area/IndicationsPsoriasisCrohn DiseaseInflammatory Bowel Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesPharmaceuticals IrelandSales LlcAllergan Plc +[6] 
Inactive CompaniesMedimmune Ltd
Active IndicationsCrohn DiseaseColitis, Ulcerative
Inactive IndicationsPsoriasisInflammatory Bowel Diseases

Other Information

ATC CodeN/A
Related LinksN/A